培美替尼是世上首个肝内胆管癌靶向药

On April 18, 2020, the U.S. Food and Drug Administration accelerated the approval of pemigatinib. Pemetinib is an FGFR2 inhibitor and is suitable for patients with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement. FGFR2 inhibitor is the first targeted drug for the treatment of cholangiocarcinoma. This targeted breakthrough therapy brings good news to patients with cholangiocarcinoma.

The approval of pemigatinib was based on the results of a clinical trial involving 107 patients with locally advanced or metastatic cholangiocarcinoma. These patients have been previously treated and carry FGFR2 (fibroblast growth factor receptor 2) fusions or rearrangements. The trial results showed that the overall response rate (ORR) of pemetinib reached 36%, of which 2.8% of patients had complete response and 33% of patients had partial response. Of the 38 patients who experienced a response, 24 patients (63%) had a response that lasted 6 months or longer, and 7 patients (18%) had a response that lasted 12 months or longer.

Pemigatinib has not been approved for sale in China, and it has not yet been included in the national medical insurance to provide everyone with preferential policies. This means that patients will not be able to buy pemetinib at all in the country. Faced with this situation, more patients choose to go to distant overseas countries to purchase medicines under huge financial pressure. However, this method costs a lot of manpower, material resources and financial resources, which is miserable. However, according to Medical Companion Travel, the pemetinib version is very cost-effective and has been well received by many patients. The specification is 13.5mgx14 tablets and the price is about 341,175$. However, because the price of the drug rises and falls with the fluctuation of the exchange rate in the market, the specific price of the drug is not stable. For more information about pemetinib, please contact Medical Travel for details.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.